Maravai LifeSciences Q4 Loss Narrows to $0.04; Revenue Beats at $49.87M
Maravai LifeSciences reported a Q4 adjusted loss of $0.04 per share, beating the consensus estimate of a $0.07 loss by 40%. Revenue for the quarter was $49.87 million, surpassing estimates by 1.21% but down from $56.56 million a year ago.
1. Q4 Financial Results
Maravai LifeSciences posted an adjusted loss of $0.04 per share for Q4, outperforming the expected loss of $0.07 by 40.03%. Revenue reached $49.87 million, topping the $49.27 million consensus by 1.21% but representing an 11.8% drop from $56.56 million in the prior-year quarter.
2. Earnings Surprise History
This quarter marked only the second time in the last four quarters that Maravai LifeSciences surpassed consensus revenue estimates, while EPS surprises have been mixed: a +40% surprise in Q4 versus a –33.3% surprise in the previous quarter.
3. Outlook and Industry Context
Consensus estimates for the upcoming quarter stand at a $0.05 loss on $57.61 million in revenue, with full-year 2026 estimates at a $0.22 loss on $210.65 million in revenue. The Medical Products industry ranks in the bottom 44% of its peer group, highlighting challenging sector dynamics.